UY32738A - Nuevos sales de fumarato de un antagonista del receptor de histamina h3 - Google Patents

Nuevos sales de fumarato de un antagonista del receptor de histamina h3

Info

Publication number
UY32738A
UY32738A UY0001032738A UY32738A UY32738A UY 32738 A UY32738 A UY 32738A UY 0001032738 A UY0001032738 A UY 0001032738A UY 32738 A UY32738 A UY 32738A UY 32738 A UY32738 A UY 32738A
Authority
UY
Uruguay
Prior art keywords
salts
new smoke
histamine
receiver antagonist
antagonist
Prior art date
Application number
UY0001032738A
Other languages
English (en)
Inventor
Beverly C Langevin
Sherer Daniel
Dinubhai H Shah
Farr Robert Allan
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32738A publication Critical patent/UY32738A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La descripción se refiere a sales de fumarato de 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida, a sus composiciones farmacéuticas, procedimientos para elaborarlas y a sus métodos de uso.
UY0001032738A 2009-06-26 2010-06-25 Nuevos sales de fumarato de un antagonista del receptor de histamina h3 UY32738A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068309P 2009-06-26 2009-06-26
FR0959110 2009-12-17

Publications (1)

Publication Number Publication Date
UY32738A true UY32738A (es) 2011-01-31

Family

ID=43386878

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032738A UY32738A (es) 2009-06-26 2010-06-25 Nuevos sales de fumarato de un antagonista del receptor de histamina h3

Country Status (25)

Country Link
US (1) US8664245B2 (es)
EP (1) EP2445899B1 (es)
JP (1) JP6053519B2 (es)
KR (1) KR101804749B1 (es)
CN (1) CN102803247B (es)
AR (1) AR077223A1 (es)
AU (1) AU2010264422B2 (es)
BR (1) BRPI1011258A2 (es)
CA (1) CA2766154C (es)
CO (1) CO6480943A2 (es)
DO (1) DOP2011000398A (es)
ES (1) ES2587064T3 (es)
IL (1) IL216924A0 (es)
MA (1) MA33378B1 (es)
MX (1) MX2011012824A (es)
NZ (1) NZ597219A (es)
PE (1) PE20121403A1 (es)
PL (1) PL2445899T3 (es)
RU (1) RU2537847C2 (es)
SG (1) SG176645A1 (es)
TN (1) TN2011000620A1 (es)
TW (1) TWI462915B (es)
UY (1) UY32738A (es)
WO (1) WO2010151611A1 (es)
ZA (1) ZA201108838B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
EP0306375A1 (fr) 1987-08-07 1989-03-08 Synthelabo Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
IL89156A (en) 1988-07-12 1993-05-13 Synthelabo Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics
WO2001009101A1 (en) 1999-07-29 2001-02-08 EGIS Gyógyszergyár Rt. Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1461311A2 (en) 2001-12-26 2004-09-29 Bayer HealthCare AG Urea derivatives as vr1-antagonists
US7790231B2 (en) 2003-07-10 2010-09-07 Brewer Science Inc. Automated process and apparatus for planarization of topographical surfaces
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
WO2006103045A1 (en) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
JP2009530274A (ja) * 2006-03-15 2009-08-27 ワイス ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
WO2008144305A1 (en) * 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
WO2009012252A1 (en) * 2007-07-16 2009-01-22 Wyeth Aminoalkylazole derivatives as histamine-3 antagonists

Also Published As

Publication number Publication date
RU2537847C2 (ru) 2015-01-10
JP6053519B2 (ja) 2016-12-27
EP2445899A1 (en) 2012-05-02
CN102803247A (zh) 2012-11-28
PL2445899T3 (pl) 2017-08-31
PE20121403A1 (es) 2012-11-02
CN102803247B (zh) 2014-11-05
NZ597219A (en) 2013-05-31
SG176645A1 (en) 2012-01-30
WO2010151611A1 (en) 2010-12-29
AR077223A1 (es) 2011-08-10
DOP2011000398A (es) 2012-01-31
BRPI1011258A2 (pt) 2016-03-22
ES2587064T3 (es) 2016-10-20
KR20120039555A (ko) 2012-04-25
AU2010264422B2 (en) 2014-12-18
JP2012531424A (ja) 2012-12-10
EP2445899B1 (en) 2016-05-11
MX2011012824A (es) 2012-01-27
CA2766154A1 (en) 2010-12-29
US20120149728A1 (en) 2012-06-14
IL216924A0 (en) 2012-03-01
KR101804749B1 (ko) 2017-12-05
TN2011000620A1 (en) 2013-05-24
CO6480943A2 (es) 2012-07-16
ZA201108838B (en) 2012-08-29
RU2012102671A (ru) 2013-08-10
AU2010264422A1 (en) 2012-02-02
US8664245B2 (en) 2014-03-04
TWI462915B (zh) 2014-12-01
CA2766154C (en) 2015-04-07
TW201103911A (en) 2011-02-01
MA33378B1 (fr) 2012-06-01

Similar Documents

Publication Publication Date Title
PH12015502775A1 (en) Amino triazine derivative and pharmaceutical composition comprising the same
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
CR10963A (es) Compuestos de 2-amino pirimidina
NI201000059A (es) Inhibidores de la cinasa c-fms.
DOP2011000398A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
EA201590823A1 (ru) 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора
EA201600436A1 (ru) Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
SV2011003854A (es) Derivados de piperazina que se unen a las placas amiloides para obtener imagenes de las mismas y su uso
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
CL2012002451A1 (es) Procedimientos para preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida; uno de sus compuestos intermediarios; y la preparacion del mismo.
AR069009A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina
CY1118841T1 (el) Παραγωγα αμινοκυκλοβουτανιου, μεθοδος παρασκευης αυτων και η χρηση αυτων ως φαρμακα
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten
BR112012030004A2 (pt) antagonistas não competitivos de receptor nicotínico
AR090605A1 (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer
ECSP11011547A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
NI201100210A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3.
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
UY34316A (es) Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad
UA106380C2 (ru) Фумаратные соли антагониста гистаминового рецептора н3
EA201390966A1 (ru) Замещенные соединения [(5h-пирроло[2,1-c][1,4]бензодиазепин-11-ил)пиперазин-1-ил]-2,2-диметилпропановой кислоты в качестве обратных агонистов h1/антагонистов 5-htдвойного действия
ECSP18003671A (es) Nueva asociación entre la 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr
NI201200127A (es) Procedimiento para la preparación de 2 - ( ciclohexilmetil ) - n - { 2 - [ (2s) - 1 - metilpirrolidin - 2 - il ] etil } - 1, 2, 3, 4 - tetrahidroisoquinolin - 7 - sulfonamida.
AR109745A2 (es) Derivado de 4-pirimidinsulfamida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190207